Gene recombinant engineering strain with malonyl-coenzyme A synthesis path taking L-glutamic acid as substrate and application of gene recombinant engineering strain

By constructing a novel malonic Coenzyme A synthesis pathway with L-glutamate as substrate in genetic recombinant engineering strains, 2-oxoglutarate oxygenase and 3-hydroxy-L-glutamate aldolase are used to construct a new malonic acid Coenzyme Alkylase with L-glutamate as substrate in gene recombinant engineering strains, The co-expression with malonyl Coenzyme A reductase solves the energy sensitivity and efficiency problems of the traditional malonyl Coenzyme A synthesis pathway, and achieves efficient malonyl Coenzyme A synthesis and the yield of high-value compounds.

CN118995783APending Publication Date: 2024-11-22GUANGDONG TECHNION ISRAEL INST OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411212353.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing malonyl Coenzyme A synthesis pathway is highly sensitive to cell energy charge, and has the risk of inefficiency and overexpression toxicity, which limits its application in biosynthesis.

Method used

Construct a gene recombinant engineering strain with a novel malonic Coenzyme A synthesis pathway with L-glutamic acid as the substrate, through 2-oxoglutarate oxygenase and 3-hydroxy-L-glutamic acid aldol The co-expression of enzyme and malonyl Coenzyme A reductase achieves efficient synthesis of malonyl Coenzyme A and forms the IAM pathway.

Benefits of technology

It significantly improves the metabolic flux of malonyl Coenzyme A in cells, enhances the yield of high-value compounds with malonyl Coenzyme A as intermediate, and solves the efficiency and safety of traditional pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995783A_ABST
    Figure CN118995783A_ABST
Patent Text Reader

Abstract

The invention provides a genetic recombination engineering strain with a malonyl-coenzyme A synthesis path taking L-glutamic acid as a substrate and application of the genetic recombination engineering strain, and relates to the technical field of biological engineering. The method comprises the following steps: transfecting a recombinant expression vector with a 2-oxoglutarate oxygenase gene expression system, a 3-hydroxy-L-glutamate aldolase gene expression system and a malonyl-coenzyme A reductase or CoA acetylated aldehyde dehydrogenase gene expression system into a competent cell of a chassis strain; co-expression of 2-oxoglutarate oxygenase, 3-hydroxy-L-glutamic acid aldolase and malonyl-coenzyme A reductase can be realized, so that a synthesis path of obtaining malonyl-coenzyme A through biosynthesis by taking L-glutamic acid as a substrate in transformed cells is realized. The Yarrowia lipolytica engineering strain constructed by using the recombinant expression vector is proved to be capable of remarkably improving the yield of a high-value compound taking malonyl-coenzyme A as a biosynthesis intermediate in the Yarrowia lipolytica engineering strain.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of bioengineering technology, and in particular to a genetically recombinant engineering strain having a malonyl-CoA synthesis pathway with L-glutamic acid as a substrate and an application thereof. Background Art

[0002] Malonyl-CoA is an essential intermediate molecule in cellular metabolism and serves as an important precursor for the biosynthesis of various compounds.

[0003] Figure 1 It is a variety of compounds that can be biosynthesized using malonyl-CoA as a synthetic precursor.

[0004] Malonyl-CoA acts across multiple synthetic pathways and plays a key role in fatty acids (lipids, oleochemicals, polyunsaturated fatty acids), polyketides (flavonoids), and medicinal compounds (antibiotics, cannabinoids). As the initiator and elongator molecule in fatty acid biosynthesis, malonyl-CoA can regulate the synthesis and decomposition of fatty acids, thereby affecting energy balance and cellular function, but its role is not limited to metabolism. In medicine, it plays a vital role in signaling pathways related to human insulin sensitivity, myocardial energy metabolism, and cancer progression.

[0005] There are two classic malonyl-CoA pathways in organisms in nature. Most organisms use the standard PDH-ACC pathway: pyruvate is oxidatively decarboxylated to acetyl-CoA, and the resulting acetyl-CoA is then carboxylated to form malonyl-CoA. However, acetyl-CoA carboxylase is composed of four different subunits in bacteria and a single polypeptide chain in higher organisms, with a relatively large molecular weight. Therefore, acetyl-CoA carboxylase has the disadvantage of inefficiency, which includes the need to consume adenosine triphosphate (ATP), strict regulatory mechanisms, and the risk of increased toxicity due to overexpression.

[0006] The second classical pathway relies on ATP-dependent malonyl-CoA synthetase, which directly acylates malonate to form malonyl-CoA at the expense of a high-energy phosphate bond. This reaction exists in the mitochondrial matrix of some bacteria, archaea, and higher organisms, and is similar to yeast cells directly synthesizing acetyl-CoA from acetate. However, both classical pathways are highly sensitive to cellular energy charge, and therefore have a significant bottleneck restriction on biosynthesis.

[0007] Therefore, it is necessary and urgent to study and construct a recombinant engineered strain with a new, unreported atypical malonyl-CoA synthesis pathway to increase the expression of malonyl-CoA, and thereby increase the production of high-value compounds with malonyl-CoA as a synthetic intermediate.

[0008] In view of this, the present invention is proposed. Summary of the invention

[0009] The object of the present invention is to provide a genetically recombinant engineered strain having a malonyl-CoA synthesis pathway with L-glutamic acid as a substrate, which can effectively increase the metabolic flux of malonyl-CoA in cells. The recombinant engineered strain having the above-mentioned synthesis pathway is applied to the construction of a Yarrowia lipolytica engineered strain, which can effectively increase the yield of high-value compounds with malonyl-CoA as a biosynthetic intermediate.

[0010] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0011] According to one aspect of the present invention, a recombinant expression vector, the backbone vector of the recombinant expression vector is pYLXP' or pUrlp, and comprises the following operably connected elements:

[0012] (a) a 2-oxoglutarate oxygenase expression system, which comprises the following elements in order from 5' to 3': a promoter, a 2-oxoglutarate oxygenase gene and a terminator;

[0013] and, (b) a 3-hydroxy-L-glutamate aldolase gene expression system, which comprises the elements from 5' to 3': a promoter, a 3-hydroxy-L-glutamate aldolase gene and a terminator;

[0014] and, (c) a malonyl-CoA reductase gene expression system, which comprises the elements, from 5' to 3', in sequence: a promoter, a malonyl-CoA reductase gene and a terminator;

[0015] The promoter in (a), (b) and (c) is a TEF promoter with an intron sequence;

[0016] The terminator in (a), (b) and (c) is the XPR2 terminator.

[0017] The recombinant expression vector provided by the present invention can achieve co-expression of 2-oxoglutarate oxygenase gene, 3-hydroxy-L-glutamate aldolase gene and malonyl-CoA reductase gene after being transfected into competent cells of chassis strains, thereby providing a basis for preparing recombinant cells that can effectively improve the metabolic flux of malonyl-CoA in cells.

[0018] In a preferred embodiment of the present invention, the (c) malonyl-CoA reductase gene expression system can be replaced by:

[0019] A CoA acetylated aldehyde dehydrogenase gene expression system, which includes elements from 5' to 3': a promoter, a CoA acetylated aldehyde dehydrogenase gene and a terminator;

[0020] The promoter is a TEF promoter with an intron sequence, and the terminator is an XPR2 terminator.

[0021] In a preferred embodiment of the present invention, the 2-oxoglutarate oxygenase expression gene is IboH, and the gene sequence of IboH is shown in SEQ ID NO.1;

[0022] The specific sequence of SEQ ID NO.1 is as follows: ATGCCCCCCACCATCCGAAACAACTTCCCCCTGTTCCACG.

[0023] In a preferred embodiment of the present invention, the 3-hydroxy-L-glutamate aldolase expression gene is LtaE, and the gene sequence of LtaE is shown in SEQ ID NO.2;

[0024] The specific sequence of SEQ ID NO.2 is as follows: ATGACCGATCAGTCTCAGCAGTTCGCCTCTGACAACTACTCTGGCATCTGTCCCGAGGCCTGGGCCGCCATGGAGAAGGCCAACCACGGCCACGAGCGAGCCTACGGCGACGATCAGTGGACCGCCCGAGCCGCCGACCACTTCCGAAAGCTGTTCGAGACCGACTGTGAGGTGTTCTTCGCCTTCAACGGCACCGCCGCCAACTCTCTGGCCCTGTCTTCTCTGTGTCAGTCTTACCACTCTGTGATCTGTTCTGAGACCGCCCACGTGGAGACCGACGAGTGTGGCGCCCCCGAGTTCTTCTCTAACGGCTCTAAGCTGCTGACCGCCCGATCTGAGGGCGGCAAGCTGACCCCCGCCTCTATCCGAGAGGTGGCCCTGAAGCGACAAGACATCCACTACCCCAAGCCCCGAGTGGTGACCATCACCCAAGCCACCGAGGTGGGCTCTGTGTACCGACCCGACGAGCTGAAGGCCATCTCTGCCACCTGTAAGGAGCTGGGCCTGAACCTGCACATGGACGGCGCTCGATTTTCTAACGCCTGTGCCTTCCTGGGCTGTACCCCCGCCGAGCTGACCTGGAAGGCCGGCATCGACGTGCTGTGTTTCGGCGGCACCAAGAACGGCATGGCCGTGGGCGAGGCCATCCTGTTCTTCAACCGAAAGCTGGCCGAGGACTTCGACTACCGATGTAAGCAAGCCGGACAGCTGGCCTCTAAGATGCGATTCCTGTCTGCCCCTTGGGTGGGCCTGCTGGAGGACGGCGCCTGGCTGCGACACGCCGCCCACGCCAACCACTGTGCTCAGCTGCTCTCTTCTCTCGTGGCCGACATCCCCGGCGTGGAGCTGATGTTCCCCGTGGAGGCCAACGGCGTGTTCCTGCAGATGTCTGAGCCCGCCCTGGAGGCCCTGCGAAACAAGGGCTGGCGATTCTACACCTTCATCGGCTCTGGCGGCGCCCGATTCATGTGCTCTTGGGACACCGAGGAGGCCCGAGTGCGAGAGCTGGCCGCCGACATCCGAGCCGTGATGTCTGCC。

[0025] In a preferred embodiment of the present invention, the malonyl-CoA reductase expression gene is MCR-C, and the gene sequence of MCR-C is shown in SEQ ID NO.3;

[0026]

[0027] In a preferred embodiment of the present invention, the CoA acetylation aldehyde dehydrogenase expression gene is StpduP, and the gene sequence of StpduP is shown in SEQ ID NO.4.

[0028]

[0029] According to one aspect of the present invention, a genetically recombinant engineered strain having a malonyl-CoA synthesis pathway with L-glutamate as a substrate, the recombinant engineered strain containing the above-mentioned recombinant expression vector;

[0030] Preferably, the chassis strain of the recombinant engineering strain includes any one of a Yarrowia lipolytica strain, a Saccharomyces cerevisiae strain, a Pichia pastoris strain, and an Escherichia coli strain.

[0031] Figure 2 This is the artificial synthesis pathway of malonyl-CoA provided in this application.

[0032] Figure 2 The synthetic pathways in the method include:

[0033] S1: 2-oxoglutarate and substrate L-glutamate are converted into 3-hydroxy-L-glutamate (3-Hydroxy-L-glutamate) using 2-oxoglutarate oxygenase (IboH) expressed in a recombinant engineering strain;

[0034] S2: 3-hydroxy-L-glutamate is broken down into malonate semialdehyde (MalSA) and glycine by 3-hydroxy-L-glutamate aldolase (LtaE) expressed in the recombinant engineered strain;

[0035] S3: Malonate semialdehyde (MalSA) is catalyzed by malonyl-CoA reductase or CoA acetylation aldehyde dehydrogenase (MCR-C / ALDH) expressed in the recombinant engineered strain and combines with coenzyme A (CoASH) to form malonyl-CoA.

[0036] See also Figure 2 It can be seen that the present application provides a new atypical malonyl-CoA synthesis pathway, the IboH-Aldolase-MCR pathway (IAM), which can obtain malonyl-CoA through biosynthesis using L-glutamate as a substrate, thereby effectively increasing the metabolic flux of malonyl-CoA in cells.

[0037] It should be noted that, through the research of this application, it is found that 2-oxoglutarate oxygenase (IboH) can hydroxylate L-glutamate and form 3-hydroxy-L-glutamate; further, 3-hydroxy-L-glutamate can be decomposed into malonate semialdehyde MalSA and glycine by 3-hydroxy-L-glutamate aldolase; malonate semialdehyde (MalSA) is combined by malonyl-CoA reductase (MCR) or CoA acetylation aldehyde dehydrogenase (ALDH), thereby forming a malonyl-CoA synthesis pathway (IAM) derived from L-glutamate. It has been verified by experiments that the above IAM pathway can effectively increase the metabolic flux of malonyl-CoA in cells, and then be used for the synthesis of high-value compounds.

[0038] According to one aspect of the present invention, the present invention provides a use of a genetically recombinant engineering strain having a malonyl-CoA synthesis pathway with L-glutamic acid as a substrate in preparing a target product high-yield engineering strain;

[0039] The genetically recombinant engineering strain with a malonyl-CoA synthesis pathway using L-glutamic acid as a substrate provided by the present invention can be widely used in the preparation process of an engineering strain with high yield of a target product.

[0040] It should be noted that malonyl-CoA has significant commercial potential in multiple industries. For example, in the pharmaceutical field, it can be used as a target for the treatment and diagnosis of metabolic diseases such as diabetes and obesity. In the field of biotechnology, it contributes to the biosynthesis of biodiesel, bioplastics and high-value chemicals. In the field of health, it can be used to synthesize high-value ω-3 or ω-6 polyunsaturated fatty acids DHA or EPA, which can be used in infant formula additives. In addition, it can also be used in the synthesis of various polypeptide antibiotic drugs, including the synthesis of macrolide antibiotics and natural analgesics such as cannabinoids. In addition, in the skin care market, malonyl-CoA derivatives can enhance the effect of anti-aging products by improving lipid metabolism. Therefore, the malonyl-CoA synthesis pathway with L-glutamate as a substrate provided in this application has broad market opportunities in the fields of health, food, energy and cosmetics.

[0041] Preferably, the target product is a product with malonyl-CoA as a biosynthetic intermediate;

[0042] More preferably, the product with malonyl-CoA as a biosynthetic intermediate includes: one of triacetic acid lactone, naringenin, orsellinic acid and olivetolic acid.

[0043] According to one aspect of the present invention, a method for constructing an engineered strain of Yarrowia lipolytica comprises:

[0044] (A) using the above-mentioned recombinant expression vector to transfect competent cells of Yarrowia lipolytica strain, and culturing to obtain transformants;

[0045] (B) The following operably linked elements are integrated into the genome of isolated transformants:

[0046] TEF promoter with intronic sequence, 2-oxoglutarate oxygenase gene and XPR2 terminator;

[0047] TEF promoter with intron sequence, 3-hydroxy-L-glutamate aldolase gene and XPR2 terminator;

[0048] TEF promoter with intronic sequence, malonyl-CoA reductase gene and XPR2 terminator;

[0049] strains to obtain recombinant engineering strains.

[0050] Preferably, the malonyl-CoA reductase gene can be replaced by a CoA acetylation aldehyde dehydrogenase gene.

[0051] In a preferred embodiment of the present invention, the competent cells of the Yarrowia lipolytica strain have the ability to synthesize any one of triacetic acid lactone, naringenin, orsellinic acid or olivetolic acid.

[0052] The invention provides a method for constructing an engineered strain of Yarrowia lipolytica, wherein a recombinant expression vector having an IboH-Aldolase-MCR pathway (IAM) is integrated into the genome of different Yarrowia lipolytica chassis strains capable of synthesizing triacetic acid lactone, naringenin, orsellinic acid and oleic acid. It has been verified that the yield of triacetic acid lactone, naringenin, orsellinic acid or oleic acid in the transformed engineered strain of Yarrowia lipolytica can be effectively increased.

[0053] In a preferred embodiment of the present invention, the Yarrowia lipolytica chassis strain is double-deficient in uracil Ura and leucine Leu. This nutritional double-deficient strain can be conveniently combined with other gene knockout and gene recombination tool vectors for synchronous transformation, thereby improving the efficiency of genetic modification projects.

[0054] According to one aspect of the present invention, an engineered strain of Yarrowia lipolytica is provided. The engineered strain of Yarrowia lipolytica is mainly prepared by the above-mentioned construction method.

[0055] Compared with the prior art, the present invention has the following beneficial effects:

[0056] After the recombinant expression vector provided by the present invention is transfected into competent cells of the chassis strain, the co-expression of the 2-oxoglutarate oxygenase gene, the 3-hydroxy-L-glutamate aldolase gene and the malonyl-CoA reductase gene can be achieved, and then the synthetic pathway (IAM) of obtaining malonyl-CoA through biosynthesis with L-glutamate as a substrate can be realized in the transformed cells, effectively improving the metabolic flux of malonyl-CoA in the cells. At the same time, the Yarrowia lipolytica engineered strain constructed using the above-mentioned recombinant expression vector has been verified to significantly increase the yield of high-value compounds with malonyl-CoA as a biosynthetic intermediate in the Yarrowia lipolytica engineered strain. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0058] Figure 1 Various compounds that can be biosynthesized using malonyl-CoA as a synthetic precursor;

[0059] Figure 2 The artificial synthesis pathway diagram of malonyl-CoA provided by the present invention;

[0060] Figure 3 The template map of the pYLXP' plasmid vector provided in Example 1 of the present invention;

[0061] Figure 4 This is a template map of the pUrlp plasmid vector provided in Example 1 of the present invention. DETAILED DESCRIPTION

[0062] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0063] The technical solution of the present invention will be further described below in conjunction with embodiments.

[0064] Example 1 Construction of recombinant expression vector

[0065] (1) Obtain pYLXP' and pUrlp plasmid vectors, both of which are from the Laboratory of Synthetic Biology and Intelligent Control, Guangdong Technion-Israel Institute of Technology.

[0066] Figure 3 This is the template map of the pYLXP' plasmid vector.

[0067] Depend on Figure 3 It can be seen that the pYLXP' vector is a circular plasmid vector containing a leucine Leu2 tag used for screening in Yarrowia lipolytica, as well as a strong promoter TEF and terminator XPR2 that function in Yarrowia lipolytica, and about 1000bp sequences upstream and downstream of the NotI restriction site are homologous arms of the pBR322 docking platform, which can integrate the carried gene into the pBR322 platform of the base strain.

[0068] Figure 4 This is the template map of the pUrlp plasmid vector.

[0069] Depend on Figure 4 It can be seen that the pUrlp vector is a circular plasmid vector containing leucine Leu2 and uracil ylUra3 tags used for screening in Yarrowia lipolytica, wherein uracil ylUra3 is controlled by the TEF promoter and the XPR2 terminator, and contains LoxP sites before TEF and after XPR2, which can realize the Cre-LoxP technology to recover the Ura gene for nutritional screening. pUrlp can be embedded in the upstream and downstream homologous arms of the site-specific insertion chromosome site for site-specific gene recombination.

[0070] (2) Double enzyme digestion of pYLXP' and pUrlp plasmid vectors was performed to obtain linearized vectors of pYLXP' and pUrlp with sticky ends.

[0071] In this example, the pYLXP' plasmid vector was double-digested with KpnI (endonuclease 1) and SnaBI (endonuclease 2).

[0072] In this example, the pUrlp plasmid vector was double-digested with NheI (endonuclease 3)-SalI (endonuclease 4).

[0073] The relevant reaction system refers to Table 1 (double enzyme digestion reaction system), wherein the reaction conditions are: 37° C., 60 min.

[0074] Table 1: Double enzyme digestion reaction system

[0075] Reagents Usage amount (μL) Carrier 8 10X Buffer 2 Endonuclease 1 / 3 1 Endonuclease 2 / 4 1 Double distilled water 8

[0076] When the enzyme digestion reaction is completed, gel electrophoresis is used to determine whether the digestion is successful.

[0077] The linearized pYLXP' vector fragments were separated by agarose gel electrophoresis, and the target vector fragments in the linearized pYLXP' vector fragments were recovered by a DNA gel recovery test kit to obtain the purified pYLXP' linearized vector fragments.

[0078] Agarose gel electrophoresis is a method used to separate DNA fragments based on their length.

[0079] The DNA gel recovery test kit is a kit used to recover the desired gene fragments from DNA agarose gel.

[0080] That is to say, the DNA fragments cut out from the pYLXP' vector can be recovered by the DNA gel recovery test kit, that is, the pYLXP' fragment is a gene fragment formed after double enzyme digestion.

[0081] (3) Assemble the linearized pYXLP vector and the target gene to obtain pYLXP'-IboH, pYLXP'-LtaE, pYLXP'-MCR-C (single gene) recombinant plasmids and pYLXP'-IboH-LtaE-MCR-C (multiple gene) recombinant plasmids.

[0082] The pYLXP' vector was linearized and the DNA fragments of IboH, LtaE and MCR-C were amplified and synthesized by PCR. Then, the recombinant plasmids pYLXP'-IboH, pYLXP'-LtaE and pYLXP'-MCR-C (single gene) were constructed respectively by seamless cloning and Gibson assembly.

[0083] Table 2: List of main primers for seamless cloning Gibson construction:

[0084]

[0085] Table 3: PCR reaction conditions:

[0086]

[0087] The pYLXP'-IboH, pYLXP'-LtaE, and pYLXP'-MCR-C (single gene) recombinant plasmids of different genes were digested by two combinations of NheI (endonuclease 3) + SalI (endonuclease 4) and AvrII (endonuclease 5) + SalI (endonuclease 4), respectively, and the target single gene band was recovered by agarose gel electrophoresis and DNA gel again. Since NheI and AvrII have the same enzyme-cut sticky ends, the recovered DNA fragments with the target genes can be assembled by multi-gene subcloning using T4 ligase, and finally the pYLXP'-IboH-LtaE-MCR-C (multi-gene) recombinant plasmid was constructed.

[0088] Table 4: T4 ligase reaction system:

[0089] Reagents Usage amount (μL) Vector gene fragment 2 Insert gene fragment 2 T4 Ligase 1 10X Buffer 1 Double distilled water 4

[0090] (3) Assemble the linearized pUrlp vector and the pYLXP'-IboH-LtaE-MCR-C (multi-gene) recombinant plasmid to obtain the site-specific integration pUrlp-IboH-LtaE-MCR-C gene site-specific recombination recombinant plasmid.

[0091] The pYLXP'-IboH-LtaE-MCR-C (multi-gene) recombinant plasmid can be digested with AvrII (endonuclease 5) + SalI (endonuclease 4), and then connected and assembled with the above-mentioned linearized pUrlp vector by T4 ligase to obtain the site-specific integration pUrlp-IboH-LtaE-MCR-C gene site-specific recombination recombinant plasmid, using the same method as above.

[0092] Example 2 Preparation of an engineered strain of Yarrowia lipolytica for high production of triacetic acid lactone

[0093] (1) Prepare competent cells of the Yarrowia lipolytica chassis strain capable of synthesizing triacetic acid lactone.

[0094] The chassis strain is cultured using a non-selective yeast culture medium YPD, wherein the chassis strain is a Yarrowia lipolytica strain that is double-deficient in leucine LEU and uracil URA and has the ability to synthesize triacetic acid lactone;

[0095] The genotype of the Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA and the ability to synthesize triacetic acid lactone is: po1fk origin; 2-PS gene integrated at KU70 site; po1fkΔku70::2-PS::loxP.

[0096] Note: The above-mentioned Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA capable of synthesizing triacetic acid lactone is stored and backed up in this unit and can be sold to the outside.

[0097] Specifically:

[0098] Take 1 mL of overnight bacterial liquid and centrifuge at low speed, discard the supernatant, and thoroughly mix and shake the precipitate with 95 μL 50% PEG4000 and 5 μL 2M lithium acetate solution to form competent cells.

[0099] The culture conditions are as follows: the chassis strain is inoculated into a test tube containing 3 mL YPD medium, and cultured in a shaking incubator at 30° C. and a rotation speed of 250 rpm.

[0100] The non-selective yeast culture medium is YPD (Yeast extract peptone dextrose), which includes 10 g / L yeast extract, 20 g / L glucose and 20 g / L peptone.

[0101] (2) The recombinant expression vector (pYLXP'-IboH-LtaE-MCR-C or pUrlp-IboH-LtaE-MCR-C) obtained in Example 1 was linearized and transformed into the competent cells prepared in the previous step.

[0102] Specific methods include:

[0103] 1. pYLXP'-IboH-LtaE-MCR-C was digested with NotI (endonuclease 6), and then the linearized vector was obtained by agarose gel electrophoresis and DNA gel recovery;

[0104] pUrlp-IboH-LtaE-MCR-C was digested with AvrII (endonuclease 5), and the linearized vector was obtained by agarose gel electrophoresis and DNA gel recovery;

[0105] 2. Mix the obtained linearized vector (0.25-0.5 μg or 5 μL) and 5 μL of boiled ssDNA (deformed fish sperm DNA) thoroughly, and add it to the competent cells prepared in the previous step;

[0106] Incubate in a 30°C water bath for 30-45 minutes, vortexing for 15 seconds every 10 minutes;

[0107] Heat shock at 39°C for 10 min;

[0108] 3. Apply the corresponding screening plates. If the transformed pYLXP'-IboH-LtaE-MCR-C contains the LEU marker, apply the CSM-Leu plate; if the transformed pUrlp-IboH-LtaE-MCR-C contains the URA3 marker, apply the CSM-ura plate.

[0109] The conventional yeast synthetic shedding defect (SD) medium formula is as follows: 20 g / L glucose, 1.7 g / L yeast nitrogen matrix without ammonium sulfate, 5 g / L ammonium sulfate ((NH4)SO4), and 1.29 g / L defective amino acids lacking leucine Leu or uracil Ura.

[0110] (3) Recover the URA gene through nutritional screening by Cre-LoxP technology,

[0111] This step is only for the engineered strain transformed with the pUrlp-IboH-LtaE-MCR-C vector;

[0112] The genome-integrated strain carrying the target IboH-LtaE-MCR-C gene obtained in the previous step is transformed into a Cre enzyme expression vector, and the URA gene can be screened through Cre recovery nutrition to regain the uracil Ura-deficient strain, so that the pUrlp vector plasmid can be used again to carry out multi-gene and multi-copy number integration transformation of the target strain.

[0113] (4) Screen and obtain an engineered strain of Yarrowia lipolytica that integrates a novel malonyl-CoA (IAM) metabolic pathway.

[0114] The Yarrowia lipolytica engineered bacteria transformed to obtain a novel malonyl-CoA (IAM) metabolic pathway are fermented in a YPD liquid medium at 30° C. for 4 to 5 days.

[0115] The non-selective yeast culture medium is YPD (Yeast extract peptone dextrose), which includes 10 g / L yeast extract, 80 g / L glucose and 20 g / L peptone.

[0116] The fermentation conditions are as follows: the transformed Yarrowia lipolytica is placed in a 250 mL baffled flask with a liquid volume of 30 mL.

[0117] (5) Product identification:

[0118] To quantify the concentration of triacetin, 400 μL of whole cell culture was taken and treated with 400 μL of ethyl acetate (0.05% formic acid) and glass beads (0.5 mm) using a three-dimensional centrifugal cryogenic sample grinder at -20°C. The grinding speed was 21 m / s for 60 s, with a 15 s interval, and repeated 30 cycles.

[0119] After the initial extraction, 300 μL of the ethyl acetate organic layer was transferred to a new microcentrifuge tube. Two more extractions were performed, each with 400 μL of ethyl acetate (0.05% formic acid), and then 300 μL of the upper extract was mixed with the previous extraction. The organic portion was then evaporated using an Eppendorf concentrator, and the dried extract was resuspended in methanol / HO (80 / 20) and vortexed for 1 minute.

[0120] The extracts were then subjected to HPLC analysis using a 1260infinity liquid chromatograph and a reversed-phase C18 column (ZORBAX Eclipse Plus C18, 4.6 × 100 mm, 3.5 μm, Agilent) connected to a diode array detector (210, 270 nm).

[0121] The mobile phase was set to solvent A (water containing 0.05% formic acid) and solvent B (methanol). The compounds were separated by gradient elution, and the proportion of solvent B was linearly increased from 60% to 100% in 20 minutes, maintained at 100% for 4.0 minutes, decreased from 100% to 60% in 1 minute, and maintained at 60% for 2 minutes.

[0122] LC-MS analysis was performed using a Thermo Scientific Orbitrap Exploris 120 mass spectrometer equipped with a heated electrospray ionization source (HESI).

[0123] Chromatographic separation was performed on an Accucore C18 HPLC column (2.6 μm, 2.1 x 150 mm). The mobile phase was 0.1% formic acid in water (phase A) and methanol (phase B), with a gradient of: 0 min, 5% B; 0.5 min, 5% B; 13 min, 95% B; 16.9 min, 95% B; 17 min, 5% B; 20 min, 5% B. The mass range of mass spectrometry detection was 100-1000 m / z, with collision energies of 20, 50, and 80 eV. Compound identification was performed using multiple database and spectral library automatic search tools (including mzCloud, Chemspider, KEGG, and BioCyc) as well as local database search tools (such as mzVault spectral library and mass list).

[0124] (6) Take the Yarrowia lipolytica engineered strain (5*10 7 CFU / mL) 600 μL was added to 30 ml fermentation medium and shaken for 1 week;

[0125] At the same time, the Yarrowia lipolytica chassis strain having the ability to synthesize triacetic acid lactone in step (1) is used as a control for cultivation.

[0126] The fermentation medium includes yeast fully synthetic conventional medium (CSM, containing 40.0 g / L glucose, 1.7 g / L yeast nitrogen base without ammonium sulfate, 5.0 g / L ammonium sulfate, and 0.74 g / L CSM-Leu);

[0127] The shaking flask culture conditions are: 30° C., 250 rpm to 300 rpm.

[0128] After one week of shake flask culture, it was finally verified that the malonyl-CoA synthesis pathway of the present application can increase the yield of the terminal product triacetate lactone by 6 times. The shake flask yields are:

[0129]

[0130] Example 3 Preparation of an engineered strain of Yarrowia lipolytica that produces high naringenin production

[0131] (1) Prepare competent cells of the Yarrowia lipolytica chassis strain capable of synthesizing naringenin.

[0132] The chassis strain is cultured using a non-selective yeast culture medium YPD, wherein the chassis strain is a Yarrowia lipolytica strain that is double-deficient in leucine LEU and uracil URA and has the ability to synthesize naringenin;

[0133] The genotype of the Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA and capable of synthesizing naringenin is: po1fk origin; RtTAL-Pc4CL-PhCHSx5-MsCHI gene integrated at KU70 site; po1fkΔku70::RtTAL-Pc4CL-Ph CHSx5-MsCHI::loxP.

[0134] Note: The above-mentioned Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA capable of synthesizing naringenin is stored and backed up in this unit and can be sold to the outside.

[0135] Specifically:

[0136] Take 1 mL of overnight bacterial liquid and centrifuge at low speed, discard the supernatant, and thoroughly mix and shake the precipitate with 95 μL 50% PEG4000 and 5 μL 2M lithium acetate solution to form competent cells.

[0137] The culture conditions and non-selective yeast culture medium are the same as those in Example 2.

[0138] (2) The recombinant expression vector (pYLXP'-IboH-LtaE-MCR-C or pUrlp-IboH-LtaE-MCR-C) obtained in Example 1 was linearized and transformed into the competent cells prepared in the previous step.

[0139] The specific method can be carried out by referring to step (2) in Example 2.

[0140] (3) Recover the URA gene through nutritional screening using Cre-LoxP technology.

[0141] The specific method can be carried out by referring to step (3) in Example 2.

[0142] (4) Screen and obtain an engineered strain of Yarrowia lipolytica that integrates a novel malonyl-CoA (IAM) metabolic pathway.

[0143] The Yarrowia lipolytica engineered bacteria transformed to obtain a novel malonyl-CoA (IAM) metabolic pathway are fermented in a YPD liquid medium at 30° C. for 4 to 5 days.

[0144] The non-selective yeast culture medium and fermentation conditions are the same as those in Example 2.

[0145] (5) Product identification:

[0146] To quantify the concentration of naringenin, 400 μL of whole cell culture was taken and treated using a three-dimensional centrifugal cryogenic sample grinder with 400 μL of ethyl acetate (0.05% formic acid) and glass beads (0.5 mm) at -20°C. The grinding speed was 21 m / s for 60 s with a 15 s interval, and 30 cycles were repeated.

[0147] After the initial extraction, 300 μL of the ethyl acetate organic layer was transferred to a new microcentrifuge tube. Two more extractions were performed, each with 400 μL of ethyl acetate (0.05% formic acid), and then 300 μL of the upper extract was mixed with the previous extraction. The organic portion was then evaporated using an Eppendorf concentrator, and the dried extract was resuspended in methanol / HO (80 / 20) and vortexed for 1 minute.

[0148] The extract was then analyzed by HPLC using a 1260infinity liquid chromatograph and a reverse phase C18 column (ZORBAX Eclipse Plus C18, 4.6×100 mm 3.5 μm, Agilent) connected to a diode array detector (210, 270 nm). The specific analysis parameters were the same as in Example 2.

[0149] LC-MS analysis was performed using a Thermo Scientific Orbitrap Exploris 120 mass spectrometer equipped with a heatable electrospray ionization source (HESI). Specific analysis parameters were the same as in Example 2.

[0150] (6) Take the Yarrowia lipolytica engineered strain (5*10 7 CFU / mL) 600 μL was added to 30 ml fermentation medium and shaken for 1 week;

[0151] At the same time, the Yarrowia lipolytica chassis strain having the ability to synthesize naringenin in step (1) was used as a control for cultivation.

[0152] The fermentation medium includes yeast fully synthetic conventional medium (CSM, containing 40.0 g / L glucose, 1.7 g / L yeast nitrogen base without ammonium sulfate, 5.0 g / L ammonium sulfate, and 0.74 g / L CSM-Leu);

[0153] The shaking flask culture conditions are: 30° C., 250 rpm to 300 rpm.

[0154] After one week of shake flask culture, it was finally verified that the malonyl-CoA synthesis pathway of the present application can increase the yield of the terminal product naringenin by 8 times. The shake flask yields are:

[0155]

[0156] Example 4 Preparation of an engineered strain of Yarrowia lipolytica for high production of lysine

[0157] (1) Prepare competent cells of the Yarrowia lipolytica chassis strain capable of synthesizing lysine.

[0158] The chassis strain is cultured using a non-selective yeast culture medium YPD, wherein the chassis strain is a Yarrowia lipolytica strain that is double-deficient in leucine LEU and uracil URA and has the ability to synthesize lysine;

[0159] The genotype of the Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA and the ability to synthesize mossic acid is: po1fk origin; RtTAL-Pc4CL-PhCHSx5-MsCHI gene integrated at KU70 site; po1fkΔku70::RtTAL-Pc4CL-Ph CHSx5-MsCHI::loxP.

[0160] Note: The above-mentioned Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA and capable of synthesizing lysine is stored and backed up in this unit and can be sold to the outside.

[0161] Specifically:

[0162] Take 1 mL of overnight bacterial liquid and centrifuge at low speed, discard the supernatant, and thoroughly mix and shake the precipitate with 95 μL 50% PEG4000 and 5 μL 2M lithium acetate solution to form competent cells.

[0163] The culture conditions and non-selective yeast culture medium are the same as those in Example 2.

[0164] (2) The recombinant expression vector (pYLXP'-IboH-LtaE-MCR-C or pUrlp-IboH-LtaE-MCR-C) obtained in Example 1 was linearized and transformed into the competent cells prepared in the previous step.

[0165] The specific method can be carried out by referring to step (2) in Example 2.

[0166] (3) Recover the URA gene through nutritional screening by Cre-LoxP technology,

[0167] The specific method can be carried out by referring to step (3) in Example 2.

[0168] (4) Screen and obtain an engineered strain of Yarrowia lipolytica that integrates a novel malonyl-CoA (IAM) metabolic pathway.

[0169] The Yarrowia lipolytica engineered bacteria transformed to obtain a novel malonyl-CoA (IAM) metabolic pathway are fermented in a YPD liquid medium at 30° C. for 4 to 5 days.

[0170] The non-selective yeast culture medium and fermentation conditions are the same as those in Example 2.

[0171] (5) Product identification:

[0172] To quantify the concentration of orsellinic acid, 400 μL of whole cell culture was taken and treated with 400 μL of ethyl acetate (0.05% formic acid) and glass beads (0.5 mm) using a three-dimensional centrifugal cryogenic sample grinder at -20° C. The grinding speed was 21 m / s for 60 s with a 15 s interval, and 30 cycles were repeated.

[0173] After the initial extraction, 300 μL of the ethyl acetate organic layer was transferred to a new microcentrifuge tube. Two more extractions were performed, each with 400 μL of ethyl acetate (0.05% formic acid), and then 300 μL of the upper extract was mixed with the previous extraction. The organic portion was then evaporated using an Eppendorf concentrator, and the dried extract was resuspended in methanol / HO (80 / 20) and vortexed for 1 minute.

[0174] The extract was then analyzed by HPLC using a 1260infinity liquid chromatograph and a reverse phase C18 column (ZORBAX Eclipse Plus C18, 4.6×100 mm 3.5 μm, Agilent) connected to a diode array detector (210, 270 nm). The specific analysis parameters were the same as in Example 2.

[0175] LC-MS analysis was performed using a Thermo Scientific Orbitrap Exploris 120 mass spectrometer equipped with a heatable electrospray ionization source (HESI). Specific analysis parameters were the same as in Example 2.

[0176] (6) Take the Yarrowia lipolytica engineered strain (5*10 7 CFU / mL) 600 μL was added to 30 ml fermentation medium and shaken for 1 week;

[0177] At the same time, the Yarrowia lipolytica strain having the ability to synthesize lysine acid in step (1) is used as a control for cultivation.

[0178] The fermentation medium includes yeast fully synthetic conventional medium (CSM, containing 40.0 g / L glucose, 1.7 g / L yeast nitrogen base without ammonium sulfate, 5.0 g / L ammonium sulfate, and 0.74 g / L CSM-Leu);

[0179] The shaking flask culture conditions are: 30° C., 250 rpm to 300 rpm.

[0180] After one week of shake flask culture, it was finally verified that the new malonyl-CoA synthesis pathway can increase the yield of the terminal product lysine by 6 times. The shake flask yields are:

[0181]

[0182] Example 5 Preparation of an engineered strain of Yarrowia lipolytica for high olive alcohol acid production

[0183] (1) Prepare competent cells of Yarrowia lipolytica chassis strain capable of synthesizing olive oil acid.

[0184] The base strain is cultured using a non-selective yeast culture medium YPD, wherein the base strain is a Yarrowia lipolytica strain that is double-deficient in leucine LEU and uracil URA and has the ability to synthesize olivetol acid;

[0185] The genotype of the Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA and capable of synthesizing olivetolic acid is: po1fk origin; KU70 site integration of PplvaE-CsOLS-CsOAC gene; po1fkΔku70::PplvaE-CsOLS-CsOAC::loxP.

[0186] Note: The above-mentioned Yarrowia lipolytica strain with double deficiency of leucine LEU and uracil URA and capable of synthesizing olivetolic acid is stored and backed up in this unit and can be sold to the outside.

[0187] Specifically:

[0188] Take 1 mL of overnight bacterial liquid and centrifuge at low speed, discard the supernatant, and thoroughly mix and shake the precipitate with 95 μL 50% PEG4000 and 5 μL 2M lithium acetate solution to form competent cells.

[0189] The culture conditions and non-selective yeast culture medium are the same as those in Example 2.

[0190] (2) The recombinant expression vector (pYLXP'-IboH-LtaE-MCR-C or pUrlp-IboH-LtaE-MCR-C) obtained in Example 1 was linearized and transformed into the competent cells prepared in the previous step.

[0191] The specific method can be carried out by referring to step (2) in Example 2.

[0192] (3) Recover the URA gene through nutritional screening by Cre-LoxP technology,

[0193] The specific method can be carried out by referring to step (3) in Example 2.

[0194] (4) Screen and obtain an engineered strain of Yarrowia lipolytica that integrates a novel malonyl-CoA (IAM) metabolic pathway.

[0195] The Yarrowia lipolytica engineered bacteria transformed to obtain a novel malonyl-CoA (IAM) metabolic pathway are fermented in a YPD liquid medium at 30° C. for 4 to 5 days.

[0196] The non-selective yeast culture medium and fermentation conditions are the same as those in Example 2.

[0197] (5) Product identification:

[0198] To quantify the concentration of orsellinic acid, 400 μL of whole cell culture was taken and treated with 400 μL of ethyl acetate (0.05% formic acid) and glass beads (0.5 mm) using a three-dimensional centrifugal cryogenic sample grinder at -20° C. The grinding speed was 21 m / s for 60 s with a 15 s interval, and 30 cycles were repeated.

[0199] After the initial extraction, 300 μL of the ethyl acetate organic layer was transferred to a new microcentrifuge tube. Two more extractions were performed, each with 400 μL of ethyl acetate (0.05% formic acid), and then 300 μL of the upper extract was mixed with the previous extraction. The organic portion was then evaporated using an Eppendorf concentrator, and the dried extract was resuspended in methanol / HO (80 / 20) and vortexed for 1 minute.

[0200] The extract was then analyzed by HPLC using a 1260infinity liquid chromatograph and a reverse phase C18 column (ZORBAX Eclipse Plus C18, 4.6×100 mm 3.5 μm, Agilent) connected to a diode array detector (210, 270 nm). The specific analysis parameters were the same as in Example 2.

[0201] LC-MS analysis was performed using a Thermo Scientific Orbitrap Exploris 120 mass spectrometer equipped with a heatable electrospray ionization source (HESI). Specific analysis parameters were the same as in Example 2.

[0202] (6) Take the Yarrowia lipolytica engineered strain (5*10 7CFU / mL) 600 μL was added to 30 ml fermentation medium and shaken for 1 week;

[0203] At the same time, the Yarrowia lipolytica chassis strain having the ability to synthesize olive alcohol acid in step (1) is used as a control for cultivation.

[0204] The fermentation medium includes yeast fully synthetic conventional medium (CSM, containing 40.0 g / L glucose, 1.7 g / L yeast nitrogen base without ammonium sulfate, 5.0 g / L ammonium sulfate, and 0.74 g / L CSM-Leu);

[0205] The shaking flask culture conditions are: 30° C., 250 rpm to 300 rpm.

[0206] After one week of shake flask culture, it was finally verified that the new malonyl-CoA synthesis pathway can increase the yield of the terminal product olive alcohol acid by 6 times. The shake flask yields are:

[0207]

[0208] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A recombinant expression vector, characterized in that: The backbone vector of the recombinant expression vector is pYLXP' or pUrlp, and includes the following operably connected elements: (a) a 2-oxoglutarate oxygenase gene expression system, which comprises the following elements in order from 5' to 3': a promoter, a 2-oxoglutarate oxygenase gene and a terminator; and, (b) a 3-hydroxy-L-glutamate aldolase gene expression system, which comprises the elements from 5' to 3': a promoter, a 3-hydroxy-L-glutamate aldolase gene and a terminator; and, (c) a malonyl-CoA reductase gene expression system, which comprises the elements, from 5' to 3', in sequence: a promoter, a malonyl-CoA reductase gene and a terminator; The promoter in (a), (b) and (c) is a TEF promoter with an intron sequence; The terminator in (a), (b) and (c) is the XPR2 terminator.

2. The recombinant expression vector according to claim 1, characterized in that The (c) malonyl-CoA reductase gene expression system can be replaced by: A CoA acetylated aldehyde dehydrogenase gene expression system, which includes elements from 5' to 3': a promoter, a CoA acetylated aldehyde dehydrogenase gene and a terminator; The promoter is a TEF promoter with an intron sequence, and the terminator is an XPR2 terminator.

3. The recombinant expression vector according to any one of claims 1 or 2, characterized in that The 2-oxoglutarate oxygenase expression gene is IboH, and the gene sequence of IboH is shown in SEQ ID NO.1; And / or, the 3-hydroxy-L-glutamate aldolase expression gene is LtaE, and the gene sequence of LtaE is shown in SEQ ID NO.2; And / or, the malonyl-CoA reductase expression gene is MCR-C, and the gene sequence of MCR-C is shown in SEQ ID NO.3; And / or, the CoA acetylation aldehyde dehydrogenase expression gene is StpduP, and the gene sequence of StpduP is shown in SEQ ID NO.

4.

4. A genetically engineered strain having a malonyl-CoA synthesis pathway with L-glutamic acid as a substrate, characterized in that: The recombinant engineered strain contains the recombinant expression vector according to any one of claims 1 to 3; Preferably, the chassis strain of the recombinant engineering strain includes any one of a Yarrowia lipolytica strain, a Saccharomyces cerevisiae strain, a Pichia pastoris strain, and an Escherichia coli strain.

5. The recombinant engineering strain according to claim 4, characterized in that The malonyl-CoA synthesis pathway using L-glutamic acid as a substrate includes: S1: The substrate L-glutamate is converted into 3-hydroxy-L-glutamate using 2-oxoglutarate oxygenase expressed in a recombinant engineered strain; S2: 3-Hydroxy-L-glutamate is decomposed into malonate semialdehyde and glycine by 3-Hydroxy-L-glutamate aldolase expressed in the recombinant engineered strain; S3: Malonate semialdehyde is catalyzed by malonyl-CoA reductase or CoA acetylation aldehyde dehydrogenase expressed in the recombinant engineered strain and combines with coenzyme A (CoASH) to form malonyl-CoA.

6. Use of the genetically recombinant engineered strain having a malonyl-CoA synthesis pathway with L-glutamic acid as a substrate according to any one of claims 4 or 5 in preparing an engineered strain with high yield of a target product; Preferably, the target product is a product with malonyl-CoA as a biosynthetic intermediate; More preferably, the product with malonyl-CoA as a biosynthetic intermediate includes: One of triacetic acid lactone, naringenin, rutin and olive alcohol acid.

7. A method for constructing an engineered strain of Yarrowia lipolytica, characterized in that: The construction method comprises: (A) using the recombinant expression vector according to any one of claims 1 to 3 to transfect competent cells of a Yarrowia lipolytica strain, and culturing to obtain transformants; (B) The following operably linked elements are integrated into the genome of isolated transformants: TEF promoter with intronic sequence, 2-oxoglutarate oxygenase gene and XPR2 terminator; TEF promoter with intron sequence, 3-hydroxy-L-glutamate aldolase gene and XPR2 terminator; The recombinant engineering strain was obtained by constructing a strain containing a TEF promoter with an intron sequence, a malonyl-CoA reductase gene and an XPR2 terminator. Preferably, the malonyl-CoA reductase gene can be replaced by a CoA acetylation aldehyde dehydrogenase gene.

8. The method for constructing an engineered strain of Yarrowia lipolytica according to claim 7, characterized in that: The competent cells of the Yarrowia lipolytica strain have the ability to synthesize any one of triacetic acid lactone, naringenin, orsenoic acid or olivetolic acid.

9. The method for constructing an engineered strain of Yarrowia lipolytica according to claim 7, characterized in that: The Yarrowia lipolytica strain is a double-deficient type of uracil Ura and leucine Leu.

10. An engineered strain of Yarrowia lipolytica, characterized in that The Yarrowia lipolytica engineered strain is mainly prepared by the construction method described in any one of claims 7 to 9.